Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NACDS

Executive Summary

Reiterates its opposition to the Nov. 3 Federal Trade Commission consent order on the Lilly/PCS merger at a press conference in New York City Dec. 8. The Lilly/PCS order requires that access to other manufacturers' non-public pricing data be protected by a "firewall" and that PCS customers be offered the choice of an open formulary. The National Association of Chain Drug Stores claims that the firewall "will not keep manufacturers from engaging in potentially collusive activities" and that "PCS could price the open formulary to be more costly than its own formulary, thus unfairly enhancing its market share of its own products that would likely be carried on the PCS closed formulary." NACDS also objected to the five-year duration of the consent decree: "the order is inconsistent with the normal 10-year period applied by the FTC," the association said. Citizen Action, Public Citizen's Litigation and Health Research Groups, the National Council on the Aging and the Attorney General of Minnesota joined NACDS at the press conference

Reiterates its opposition to the Nov. 3 Federal Trade Commission consent order on the Lilly/PCS merger at a press conference in New York City Dec. 8. The Lilly/PCS order requires that access to other manufacturers' non-public pricing data be protected by a "firewall" and that PCS customers be offered the choice of an open formulary. The National Association of Chain Drug Stores claims that the firewall "will not keep manufacturers from engaging in potentially collusive activities" and that "PCS could price the open formulary to be more costly than its own formulary, thus unfairly enhancing its market share of its own products that would likely be carried on the PCS closed formulary." NACDS also objected to the five-year duration of the consent decree: "the order is inconsistent with the normal 10-year period applied by the FTC," the association said. Citizen Action, Public Citizen's Litigation and Health Research Groups, the National Council on the Aging and the Attorney General of Minnesota joined NACDS at the press conference.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS025449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel